ChangJinCai®-LungSeerLung Nodule Benign/Malignant Differentiation
Significance of Testing: It can assist doctors in distinguishing between benign and malignant lung nodules, helping patients choose an appropriate treatment plan.
Superior performance in detecting early-stage lung cancer (>90%)
High accuracy in distinguishing challenging nodules between 5 to 15 mm (>93%)
Requires only 0.5 mL of serum, no fasting required
High detection capability for lung cancer across different stages, subtypes, and levels of invasion
Bio-pSi®Serum Peptide Detection Kit
ClinMs-Plat®l Time-of-Flight Mass Spectrometer
HJ Cloud® AI Analytics Software
Obtained the First Medical Device Registration Certificate for Clinically Researched Peptide or Protein Fingerprinting (Certificate No.: 浙械注准20242221307) in 2024
Chosen as the Only Product in the Mass Spectrometry Proteomics Field to be Listed on the MIIT's Artificial Intelligence Medical Device Innovation Task List in 2022
Included in the Key Technical Indicators List for the First (Set) of Major Areas in Zhejiang Province's Manufacturing Industry (High-End Medical Devices) in 2023
Received Support from Multiple Key Research and Development Projects
Selected as the Sole High-End Medical Equipment in the Engineering Development Key Projects of Zhejiang Province’s Manufacturing Industry's First (Set) Product in 2022
| Testing Program | Sample size | Detection accuracy | |||
|---|---|---|---|---|---|
| Carcinoma in situ | Early stage of lung cancer (Stage I) | 5-10mm difficult nodules | benign nodule | ||
| Lung Nodule Benign/Malignant Differentiation | 11345 | 85.7% | 90.8 | 94.8% | 97.6% |
